MedTrace Logo

Chronic Liver Disease and Radiation-induced Second Primary Liver Malignancy

NCT06868394 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20846

Last updated 2025-03-11

No results posted yet for this study

Summary

Cancer survivors are at a high risk to develop second primary malignancy (SPM) which constitutes a serious threat for them. Radiotherapy is the cornerstone for the management of many cancers as a locoregional treatment modality. Due to the low liver tolerance, cirrhotic patients are at a high risk of developing radiation-induced liver toxicities despite the modern safe radiation delivery techniques. Radiation damages cells through direct energy deposition and reactive free radical generation. Recent studies demonstrated a potential risk of SPMs following radiotherapy with further investigations for strategies to decrease radiation-induced SPMs. However, it is insufficiently addressed if developing liver SPMs is a serious adverse event following radiotherapy for cirrhotic patients. The aim of this study was to quantitatively assess the risk of gastrointestinal (GI) and liver SPMs following radiotherapy in patients with chronic liver disease.

Conditions

  • Chronic Liver Disease (CLD)
  • Cancer
  • Liver Fibrosis

Interventions

RADIATION

radiotherapy

The impact of previous radiotherapy exposure was studied on developing second primary malignancies.

OTHER

No intervention

This group received no radiotherapy

Sponsors & Collaborators

  • Suez Canal University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06868394 on ClinicalTrials.gov